

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action you should take you should seek your own personal financial advice from your stockbroker, solicitor, accountant or other independent financial adviser authorised under the Financial Services and Markets Act 2000 if you are resident in the United Kingdom or, if not, another appropriately authorised independent financial adviser.

If you have sold or otherwise transferred all of your Ordinary Shares please forward this document and the accompanying Form of Proxy at once to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for delivery to the purchaser or transferee. If you have sold or otherwise transferred only some of your Ordinary Shares you should retain this document and consult with the stockbroker, bank or other agent through whom the sale or transfer was effected.

The Directors, whose names appear on page 3 of this document, accept responsibility, both individually and collectively, for the information contained in this document. To the best of the knowledge of the Directors, who have taken all reasonable care to ensure that such is the case, the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

e-Therapeutics plc

(Incorporated and registered in England and Wales with registered number 4304473)

PROPOSED ACQUISITION OF SEARCHBOLT LIMITED

NOTICE OF GENERAL MEETING

Numis Securities Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for the Company and will not be responsible to any person other than the Company under the Financial Services and Markets Act 2000, the rules of the Financial Conduct Authority or otherwise for providing the protections afforded to its clients or for advising any other person in relation to the contents of this document, the Acquisition or any matter, transaction or arrangement referred to in this document. Numis Securities Limited is not making any representation or warranty, express or implied, as to the contents of this document.

This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any securities. This document provides you with information about the Acquisition.

This document should be read as a whole. Your attention is drawn to the letter from the Chairman of the Company which is set out on pages 6 to 9 of this document and in which the Independent Directors recommend that Shareholders vote in favour of the Resolutions. Notice of the General Meeting to be held at 17 Fenlock Court, Long Hanborough, Oxfordshire, OX29 8LN at 12.00 noon on 27 May 2016 is set out on pages 10 to 12 of this document. The Form of Proxy for use at the General Meeting forms part of this document and should be returned, together with the power of attorney or other authority (if any) under which the Form of Proxy is signed or a certified copy of such power or authority, to Neville Registrars at Neville House, 18 Laurel Lane, Halesowen, West Midlands, B63 3DA by hand or by post (in each case marked for the attention of the Company Secretary) so as to be received not less than 48 hours before the time fixed for the holding of the meeting or any adjournment thereof (as the case may be). Completion and return of the Form of Proxy will not preclude Shareholders from attending and voting in person at the General Meeting should they wish to do so.

Copies of this document will be available, free of charge, for a period of one month from the date of this document, at the Company's registered office during normal business hours (Saturdays, Sundays and public holidays excepted) and at the Company's website, www.etherapeutics.co.uk.

The distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and therefore persons into whose possession this document and/or the accompanying Form of Proxy comes should inform themselves about and observe such restrictions. Any failure to comply with such restrictions may constitute a violation of the securities law of any such jurisdiction.

TABLE OF CONTENTS

	<i>Page</i>
KEY STATISTICS	2
EXPECTED TIMETABLE OF PRINCIPAL EVENTS	2
DIRECTORS, SECRETARY AND ADVISERS	3
DEFINITIONS	4
LETTER FROM THE CHAIRMAN	6
NOTICE OF A GENERAL MEETING	10

KEY STATISTICS

Issue Price per Consideration Share	14.55 pence
Number of Existing Shares	264,455,551
Minimum number of Consideration Shares to be issued in connection with Directors' undertakings	2,623,892
Maximum number of Consideration Shares to be issued	14,938,567
Enlarged Share Capital following Completion of the Acquisition if the maximum number of Consideration Shares are issued	279,394,118
Minimum number of Consideration Shares to be issued in connection with Directors' undertakings pursuant to the Acquisition as a percentage of the Enlarged Share Capital	0.94%
Enlarged Share Capital following Completion of the Acquisition if the minimum number of Consideration Shares in connection with Directors' undertakings are issued	267,079,443
Maximum number of Consideration Shares to be issued pursuant to the Acquisition as a percentage of the Enlarged Share Capital	5.35%

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

Posting of circular	11 May 2016
Latest time and date for receipt of Forms of Proxy	12.00 noon, 25 May 2016
General Meeting	12.00 noon, 27 May 2016
Admission of the Consideration Shares for the Initial Consideration	8.00 am, 3 June 2016
Completion of the Acquisition	3 June 2016

DIRECTORS, SECRETARY AND ADVISERS

Directors	Iain Ross (Chairman) Malcolm Young (Chief Executive) Steve Medlicott (Finance Director) Sean Nicolson (Executive Director) Stephen Self (Development Director) Brad Hoy (Non-executive Director) Trevor Jones (Non-executive Director)
Registered Office	17 Blenheim Office Park Long Hanborough Oxfordshire OX29 8LN
Company Secretary	Sean Nicolson
Nominated Adviser and broker	Numis Securities Limited The London Stock Exchange Building 10 Paternoster Square London EC4M 7LT
Solicitors to the Company	Bond Dickinson LLP St Ann's Wharf 112 Quayside Newcastle upon Tyne NE1 3DX
Registrar	Neville Registrars Limited Neville House 18 Laurel Lane Halesowen West Midlands B63 3DA

DEFINITIONS

“Acquisition”	the acquisition of the entire issued share capital of Searchbolt pursuant to the Offer
“Act”	the Companies Act 2006 (as amended)
“Admission”	the admission of the Consideration Shares to trading on AIM
“AIM”	AIM, a market operated by the London Stock Exchange
“AIM Rules”	the AIM Rules for Companies as published by the London Stock Exchange from time to time
“Approval”	the approval of the Company’s shareholders of the terms of the Acquisition as a substantial property transaction pursuant to section 190 of the Act
“Company”	e-Therapeutics plc
“Completion”	completion of the Acquisition
“Consideration Shares”	up to 14,938,567 Ordinary Shares to be issued to the Sellers in full or partial consideration for the acquisition of Searchbolt subject to, among other things, the passing of the Resolutions
“Directors” or “Board”	the directors of the Company whose names are set out on page 3 of this document
“Enlarged Share Capital”	the Ordinary Shares in issue immediately following Completion
“Existing Shares”	the 264,455,551 Ordinary Shares in issue at the date of this document
“Field”	<p>the application of complex systems techniques:</p> <ul style="list-style-type: none">• in which the nodes of any analysed network represent uniform resource locators and the edges between them represent hyperlinks on the world wide web; or• to additional fields relating to social media analysis, social network analysis, mobile telephony networks and the targeting of internet advertising on the basis of link structure, <p>but always excluding drug discovery and drug development applications</p>
“Form of Proxy”	the form of proxy for use in connection with the General Meeting which accompanies this document

“General Meeting”	the general meeting of the Company to be held at 12.00 noon on 27 May 2016
“Independent Directors”	the Directors other than Malcolm Young and Sean Nicolson
“Initial Consideration”	the initial consideration of approximately £1.76m in total payable to the Sellers
“Issue Price”	14.55 pence per Consideration Share
“London Stock Exchange”	London Stock Exchange plc
“Notice of General Meeting”	the notice convening the General Meeting which is set out at the end of this document
“Numis”	Numis Securities Limited
“Offer”	the conditional offer made by the Company to acquire the entire issued and to be issued share capital of Searchbolt subject to the passing of the Resolutions among other things
“Ordinary Shares”	ordinary shares of 0.1 pence each in the capital of the Company
“Resolutions”	the resolutions set out in the Notice of General Meeting
“Searchbolt”	Searchbolt Limited, incorporated in England and Wales, number 6323379
“Searchbolt Shares”	ordinary shares in the capital of Searchbolt
“Sellers”	the sellers of Searchbolt Shares
“Shareholders”	holders of Ordinary Shares

PART 1

LETTER FROM THE CHAIRMAN

e-Therapeutics plc

(Registered in England and Wales, company number 4304473)

Directors:

Iain Ross (Chairman)
Malcolm Young (Chief Executive)
Steve Medlicott (Finance Director)
Sean Nicolson (Executive Director)
Stephen Self (Development Director)
Brad Hoy (Non-Executive Director)
Trevor Jones (Non-Executive Director)

Registered Office:

17 Blenheim Office Park
Long Hanborough
Oxfordshire
OX29 8LN

11 May 2016

Dear Shareholder

Proposed Acquisition of Searchbolt and Notice of General Meeting

Introduction

The Company announced on 11 May 2016 that it had made a conditional offer to acquire Searchbolt Limited.

The Acquisition, which is being effected by way of the Offer, is conditional among other things on the passing of the Resolutions at the General Meeting. The Resolutions include the approval by the Company's shareholders of the Acquisition for the purposes of section 190 of the Act. The Approval is required as two of the Directors, Malcolm Young and Sean Nicolson, hold shares in Searchbolt and consequently the Acquisition constitutes a substantial property transaction for the purpose of section 190 of the Act.

The purpose of this letter is to explain the background to and reasons for the Acquisition, to set out why the Independent Directors consider the Acquisition to be in the best interests of the Shareholders as a whole and to seek the Shareholders' approval for the Resolutions to be proposed at the General Meeting.

Background to and reasons for the Acquisition

Searchbolt was demerged from the Company at the time of the Company's flotation in 2007. Searchbolt was established to develop internet search engine technology. At the time of the demerger, the Company granted Searchbolt an exclusive, perpetual royalty free licence of intellectual property to exploit the Company's core technology in relation to internet search engines. Under the terms of that licence, Searchbolt was granted the right to grant sub-licences and to assign the licence. The Company undertook not to grant a similar licence to other parties.

Searchbolt currently has no employees or material commercial agreements. Its principal assets comprise the benefit of the intellectual property licence granted to it by the Company in 2007, technology developed by Searchbolt itself since 2007 and internet search engine software developed by Searchbolt. For tax planning and practical reasons the Acquisition has been structured as an acquisition of Searchbolt rather than just Searchbolt's intellectual property assets.

The Independent Directors have reviewed the principal intellectual property assets held by Searchbolt. They consider that the acquisition of Searchbolt would enable the Company to:

- consolidate its ownership of the technology that is currently licensed to Searchbolt which would ensure that the Company has full control of the rights to prosecute and defend its intellectual property. Although the Company may continue its current drug discovery and development operations without acquiring Searchbolt, the consolidation of ownership of its technology offers a variety of strategic and practical benefits;

- potentially exploit its technology in the internet search and social media fields. The social media sector was nascent at the time of Searchbolt's establishment in 2007. Since that time, social media has developed into a significant business sector. The restriction of Searchbolt's licence of the Company's technology to internet search alone has limited Searchbolt's ability to develop complementary technologies in the social media field.

Details of the Acquisition

The terms of the Acquisition are set out in the Offer that has been made to the Sellers.

Under the Offer, the aggregate consideration payable by the Company to the Sellers comprises:

- Initial Consideration of approximately £1.76m payable in cash;
- retained consideration of up to approximately £563,000 payable in cash upon the receipt by Searchbolt of such sum from third parties in respect of debts owed by them to Searchbolt and the cancellation of certain of Searchbolt's shares;
- the earn out consideration referred to below.

A Seller may elect to receive some or all of his entitlement to the Initial Consideration and up to approximately £421,280 of the retained consideration by the allotment and issue of Consideration Shares at the Issue Price. The Consideration Shares will rank *pari passu* with the existing Ordinary Shares in all respects including the right to receive all dividends or other distributions declared, made or paid by the Company by reference to record dates falling after their respective dates of allotment. Application will be made to the London Stock Exchange for the Consideration Shares to be admitted to trading on AIM. Admission is expected to become effective, and dealings in the Consideration Shares to commence, at 8.00am on 3 June 2016.

The earn out consideration will be calculated as follows:

- The entitlement to the earn out shall accrue in respect of
 - a sale of Searchbolt;
 - the sale or licensing in the Field of the patents previously licensed by the Company to Searchbolt and/or patents owned outright by Searchbolt and/or the copyright in software owned outright by Searchbolt
(a "Relevant Sale")
- No earn out shall be payable until the Company has recouped the following costs:
 - £54,500;
 - all reasonable costs incurred by the Company in relation to a Relevant Sale including: legal, accounting, tax and other professional fees; finder's and all other sale fees incurred in connection with a Relevant Sale; fees payable to third parties in relation to establishing the value of the patents and the copyright the subject of the earn out entitlement and/or any possible infringements of the same by third parties;
 - revenue or royalty shares payable to any third parties in connection with any sale or licence.
- Once such costs have been recouped, the aggregate earn out will be 25% of the net proceeds of a Relevant Sale. The aggregate earn out will be subject to a maximum payment of £100,000,000 plus 0.1¹⁰% of the excess of a Relevant Sale over £400,000,000 of those Net Sale Proceeds.

The earn out consideration shall be satisfied in the same form in which it is received by the Company (whether cash, non-sterling currency, shares, warrants, options or any other non-cash consideration).

Under the Offer, certain of Searchbolt's directors will give warranties and a tax covenant to the Company. The maximum liability of such directors under such warranties and the tax covenant will be £75,000. In addition to the warranties and the tax covenant to be given by certain of Searchbolt's directors, the Company has arranged for its benefit a warranty and indemnity insurance policy which, subject to its terms, will provide aggregate insurance cover of £2,500,000 in respect of claims arising under such warranties and tax covenant.

The Offer is conditional, amongst other things, upon the passing of the Resolutions.

The Company has secured irrevocable undertakings to accept the Offer from the holders of more than 80% of the Searchbolt Shares in issue and to be issued in connection with the Acquisition. Under Searchbolt's articles of association the acceptance of the Offer by such Sellers will enable the Company to compulsorily acquire all other Searchbolt Shares, so that it acquires the entire issued and to be issued share capital of Searchbolt. Completion of the Acquisition is expected to occur in June 2016.

Undertakings of Malcolm Young and Sean Nicolson

Malcolm Young and Sean Nicolson have irrevocably undertaken to accept the Offer in respect of the Searchbolt Shares that they hold. The initial and retained consideration payable to them is set out below. In addition, Professor Young and Mr Nicolson have undertaken to elect to receive Consideration Shares in respect of that part of consideration payable to them as set out below.

	Percentage of fully diluted Searchbolt Shares held	Net Initial Consideration payable (£)	Retained consideration Payable (£)	Consideration to be settled by the issue of Consideration Shares (£)
Malcolm Young	32.80%	453,657	184,340	up to 487,458.22
Sean Nicolson	0.35%	6,062	1,944	up to 7,520.33

Related party transaction and substantial property transaction

Malcolm Young and Sean Nicolson are "related parties" of the Company as defined in the AIM Rules by virtue of being Directors of the Company. Malcolm Young is also a "related party" of the Company as defined in the AIM Rules by virtue of being a director of Searchbolt. Accordingly, the Acquisition is treated as a "related party transaction" under the AIM Rules.

The Independent Directors who are not related parties under the AIM Rules for the purposes of the Acquisition, having consulted with Numis, the Company's nominated adviser for the purpose of the AIM Rules, consider that the Acquisition is fair and reasonable insofar as the shareholders of the Company are concerned.

Malcolm Young and Sean Nicolson have not taken part in the Board's consideration of the Acquisition.

The Acquisition is a substantial property transaction involving a director of the Company for the purpose of section 190 of the Act. Accordingly, the Acquisition is subject to and conditional upon the approval of the Shareholders under section 190 of the Act and the passing of the other Resolutions.

General Meeting

Set out at the end of this document is a notice convening the General Meeting of the Company to be held at 17 Fenlock Court, Long Hanborough, Oxfordshire, OX29 8LN at 12.00 noon on 27 May 2016. The Resolutions to be proposed at the General Meeting are as follows.

Resolution 1 approves the Acquisition as a substantial property transaction for the purposes of section 190 of the Act.

Resolution 2 seeks Shareholder approval for the directors to be authorised to allot shares. Under the provisions of section 551 of the Act, the directors are not permitted to allot shares unless authorised to do so by the shareholders. At the annual general meeting of the Company held on 11 June 2015, the directors were given authority to allot ordinary shares in the capital of the Company up to approximately 70% of the Company's then issued ordinary share capital. The Directors consider it appropriate that they be granted authority to allot shares in the capital of the Company up to a maximum nominal amount of £200,078.01 representing the maximum number of Consideration Shares permitted under the Offer together with a further 70% of the Company's issued ordinary share capital following completion of the Acquisition assuming that the Sellers elect to receive the maximum number of Consideration Shares permitted under

the Offer. This power will last until the conclusion of the next annual general meeting. The Directors have no present intention of exercising this authority other than in connection with the Acquisition.

Resolution 3 supplements the directors' authority to allot shares in the Company proposed by resolution 2. Section 561 of the Act requires a company proposing to allot equity securities (which includes selling shares held in treasury) to offer them first to existing shareholders in proportion to their existing shareholdings. Equity securities include ordinary shares (the only class of share capital the Company has at present), but do not include shares issued under employee share schemes. If resolution 3 is passed, the requirement imposed by section 561 of the Act will not apply to allotments by the directors in the specific cases referred to in the resolution including:

- in connection with a rights (or similar) issue; and
- allotments of shares for cash up to a total nominal value of £55,884.69 (representing approximately 20% of the Company's issued share capital assuming that the Sellers elect to receive the maximum number of Consideration Shares permitted under the Offer). This will retain the Directors' existing flexibility to take advantage of business opportunities as they arise.

This authority will expire at the conclusion of the next annual general meeting or, if earlier, 15 months after the date of the resolution, except in so far as commitments to allot shares have been entered into before that date.

Recommendation

The Independent Directors believe that the proposed Acquisition is in the best interests of the Company and its Shareholders. Accordingly, the Independent Directors, recommend that Shareholders vote in favour of the Resolutions, as they intend to do in respect of their individual holdings amounting in aggregate to approximately 0.2% of the Company's current issued share capital.

Action to be taken

A Form of Proxy for use at the General Meeting accompanies this document. The Form of Proxy should be completed in accordance with the instructions thereon and returned to the Company's registrars, Neville Registrars Limited, at Neville House, 18 Laurel Lane, Halesowen, West Midlands, B63 3DA, UK, as soon as possible, but in any event so as to be received by no later than 48 hours before the time of the General Meeting. The completion and return of a Form of Proxy will not preclude Shareholders from attending the General Meeting and voting in person should they so wish.

Yours sincerely

Iain Ross
Chairman

NOTICE OF A GENERAL MEETING

Notice is hereby given that a general meeting of e-Therapeutics plc (Company) will be held at 17 Fenlock Court, Long Hanborough, Oxfordshire, OX29 8LN at 12.00 noon. on 27 May 2016 to consider and, if thought fit, pass the following resolutions of which resolutions 1 and 2 will be proposed as ordinary resolutions and resolution 3 will be proposed as a special resolution.

1. That the acquisition by the Company of the entire issued share capital of Searchbolt Limited (Searchbolt) on the terms and subject to the conditions contained in the offer document dated 11 May 2016 sent to the shareholders and optionholders of Searchbolt (Offer Document) be and the same is approved for the purposes of section 190 of the Companies Act 2006 and that the Independent Directors (as defined in the circular to shareholders dated 11 May 2016) be and are hereby authorised to take all steps necessary or, in the opinion of the Independent Directors, desirable to give effect to the terms of the offer set out in the Offer Document.
2. That, subject to the passing of resolution 1 above, the directors be generally and unconditionally authorised for the purpose of section 551 of the Companies Act 2006 (Act) to exercise all the powers of the Company to allot or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of £200,078.01, provided that:
 - 2.1 (except as provided in paragraph 2.2 below) this authority shall expire on the date of the next annual general meeting of the Company; and
 - 2.2 the Company may before such expiry make an offer or agreement which would or might require shares or equity securities (within the meaning of section 560 of the Act), as the case may be, to be allotted or such rights granted after such expiry and the directors may allot shares or equity securities or grant such rights, as the case may be, in pursuance of such offer or agreement notwithstanding that the authority conferred by this resolution has expired.

All unexercised authorities previously granted to the directors to allot shares or to grant rights to subscribe for or to convert any security into shares be and are hereby revoked.

3. That, subject to the passing of resolutions 1 above, the directors, pursuant to the general authority conferred on them by resolution 2 above be empowered pursuant to section 570 of the Companies Act 2006 (Act) to allot for cash, either pursuant to the authority so conferred or where the equity securities are held by the Company as treasury shares (within the meaning of section 724(5) of the Act), to allot equity securities (within the meaning of section 560 of the Act) as if section 561 of the Act did not apply to any such allotment provided that this power shall be limited to the allotment of equity securities:
 - 3.1 made in connection with the allotment of ordinary shares of 0.1 pence each in the capital of the Company pursuant to the e-Therapeutics Performance Share Plan 2013;
 - 3.2 made in connection with the allotment of up to 343,190 ordinary shares of 0.1 pence each in the capital of the Company pursuant to those option agreements referred to in paragraphs 2.9 to 2.13 of Part VII of the admission document relating to the Company dated 22 November 2007 that have neither been fully exercised nor lapsed;
 - 3.3 made in connection with the allotment and issue of up to 118,020 ordinary shares of 0.1 pence each in the capital of the Company pursuant to the options granted to Oliver James;
 - 3.4 made in connection with an offer of securities, open for acceptance for a fixed period, by the directors to ordinary shareholders of the Company on the register on a fixed record date in proportion (as nearly as may be) to their then holdings of such shares (but subject to such exclusions or other arrangements as the directors may deem necessary or expedient to deal with treasury shares or any legal or practical problems under the laws or requirements of any recognised regulatory body or any stock exchange in any overseas territory or in connection

with fractional entitlements) or by virtue of shares being represented by depositary receipts or any other matter whatsoever; and/or

- 3.5 wholly for cash (otherwise than pursuant to paragraphs 3.1 to 3.4 above) up to an aggregate nominal value of £55,884.69

and shall expire on the conclusion of the next annual general meeting of the Company or, if earlier, 15 months after the passing of this resolution, but the Company may before such expiry make an offer or agreement which would or might require equity securities to be allotted after such expiry and the directors may allot equity securities pursuant to such an offer or agreement notwithstanding that the power conferred by this resolution has expired.

All unexercised authorities previously granted to the directors under section 570 of the Act are hereby revoked.

By order of the board

Sean Nicolson

Secretary

11 May 2016

Registered office
17 Blenheim Office Park
Long Hanborough
Oxfordshire
OX298LN
United Kingdom

Incorporated in England and Wales, company number 4304473

Notes

The following notes explain your general rights as a shareholder of the Company and your right to attend and vote at this meeting or to appoint someone else to vote on your behalf.

1. Only those members registered in the register of members of the Company as 48 hours before the time set for the meeting shall be entitled to attend and vote at the meeting convened above in respect of the number of shares registered in their names at that time. This time will still apply for the purpose of determining who is entitled to attend and vote if the general meeting is adjourned from its scheduled time by 48 hours or less. If the general meeting is adjourned for longer, members who wish to attend and vote must be on the Company's register of members by 48 hours before the time fixed for the adjourned meeting. Changes to entries on the register of members after that time will be disregarded in determining the rights of any person to attend or vote at the meeting.
2. A member entitled to attend and vote at the meeting convened by the above notice is entitled to appoint another person as his or her proxy to exercise all or any of his or her rights to attend and to speak and vote at a meeting of the Company. On a poll demanded, all of a member's voting rights may be exercised by one or more duly appointed proxies. Any such member may appoint more than one proxy provided that each proxy is appointed to exercise the rights attached to a different share or shares held by such member. You may not appoint more than one proxy to exercise rights attached to any one share. To appoint more than one proxy, please contact Neville Registrars Limited at Neville House, 18 Laurel Lane, Halesowen, West Midlands, B63 3DA. A proxy need not be a member of the Company. Appointing a proxy will not prevent a member from attending in person and voting at the meeting. If you wish your proxy to speak on your behalf at the meeting you will need to appoint your own choice of proxy (not the chairman of the meeting) and give your instructions directly to them. A proxy must vote in accordance with any instructions given by the appointing member.

3. A form of appointment of proxy is enclosed. To appoint a proxy using this form in hard copy form, this form must be completed and signed, sent or delivered to Neville Registrars Limited at Neville House, 18 Laurel Lane, Halesowen, West Midlands, B63 3DA. In the case of a member that is a company, the proxy form must be executed under its common seal or signed on its behalf by an officer of the company or an attorney of the company. If you return more than one proxy appointment, either by hard copy form or by electronic form, that received last by the registrar before the latest time for the receipt of proxies will take precedence.
4. The form of proxy includes a vote withheld option. Please note that a vote withheld is not a vote in law and will not be counted in the calculation of the proportion of the votes for and against any particular resolution.
5. The appointment of a proxy and the original or duly certified copy of the power of attorney or other authority (if any) under which it is signed or authenticated should be deposited with Neville Registrars Limited at Neville House, 18 Laurel Lane, Halesowen, West Midlands, B63 3DA not later than 48 hours before the time for holding the general meeting or any adjourned meeting.
6. In the case of joint holders of shares, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first named being the most senior).
7. Copies of the following documents are available for inspection during normal business hours at the registered office of the Company on any business day and they may also be inspected on the day of the meeting until the conclusion of the meeting:
 - 7.1 the offer document sent to the shareholders and optionholders of Searchbolt Limited;
 - 7.2 the directors' service contracts with the Company; and
 - 7.3 the non-executive directors' letters of appointment.
8. Except as provided above, members who have general queries about the meeting should write to the company secretary at the Company's registered office. No other methods of communication will be accepted. You may not use any electronic address provided either in this notice of meeting or any related documents (including the chairman's letter and proxy form) to communicate with the Company for any purposes other than those expressly stated.

